Back to mobile site

Stifel on NewAmsterdam Pharma Co NV (NAMS): 'the risk/reward is very compelling'

September 21, 2026 10:13 AM EDT Send to a Friend
Stifel analyst James Condulis reiterated a Buy rating and $50.00 price target on NewAmsterdam Pharma Co NV (NASDAQ: NAMS).The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login